Open AccessNew Oral Anticoagulants and the Cancer Patient
Author(s) -
Short Nicholas J.,
Connors Jean M.
Publication year - 2014
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2013-0239
Subject(s) - medicine , dabigatran , apixaban , rivaroxaban , edoxaban , intensive care medicine , cancer , malignancy , discovery and development of direct thrombin inhibitors , atrial fibrillation , vitamin k , warfarin , thrombin , platelet
Learning ObjectivesCite the current indications, basic clinical pharmacology, and rationale for development of the new oral anticoagulants. Explain the potential risk for drug‐drug interactions between the new oral anticoagulants and drugs commonly used in cancer patients.